ClinicalTrials.gg
CompletedNCT01336608Updated Nov 8, 2017Results posted

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

A Phase 3 interventional study of Fluticasone Furoate/Vilanterol and Vilanterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 72 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
12th of 25
446 · median 229
Started
2011
with 3 others
Phase 3
7 of 25
none open now
Registered
4th of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic pulse wave velocity of 11.0 m/s or above.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis defined by ATS/ERS
  • Former or current smoker
  • A measured aortic pulse wave velocity = or > 11.0 m/s at Screening

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • A current diagnosis of asthma
  • alpha1-antitrypsin deficiency as the underlying cause of
  • subjects with other and active respiratory disorders
  • A cardiovascular event occurred in the 6 months prior to Visit 1
  • Current severe heart failure ( Class IV) and have a known of \< 30 %
  • Clinical significant and uncontrolled hypertension
  • Abnormal and clinical significant 12-lead findings at Visit 1
  • Have lung volume reduction or lung transplantation within 12 months prior to Visit 1
  • Poorly controlled COPD: Acute worsening of COPD that is managed by subject with antibiotics or , or requires treatment prescribed by a physician in the 6 weeks prior to Visit 1; or subject needs to be hospitalised due to poorly controlled COPD within 12 weeks prior to Visit 1
  • Lower respiratory tract infection that required use of antibiotics within 6 weeks prior to Visit 1
  • Participate in the acute phase of a pulmonary rehabilitation within 4 weeks prior to Visit 1 or who will enter the acute phase of pulmonary rehabilitation during the study.
  • Other diseases or abnormalities in the opinion of the investigator would put safety of the subject at risk through participation; or would affect the safety or efficacy analysis if the disease/condition exacerbated during the study.
  • subjects with carcinoma has not been in complete remission for at least 5 years. Carcinoma in site of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
  • subjects with a history of to any of the study medications or components of the inhalation powder.
  • subjects with a known or suspected history of alcohol or drug abuse within the last 2 years prior to Screening
  • subjects are medically unable to withhold albuterol or ipratropium for 4 hours prior to spirometry testing at each study visit
  • subjects are medically unable to stop the 'excluded medications' listed in the protocol
  • subjects started, discontinued certain medications listed in the protocol or have not been on a stable dose in the past three months prior to Screening, or are not anticipated to remain on a stable dose during the study treatment period.
  • Long term oxygen therapy requiring >12 hour per day or a flow rate > 2 L/min
  • A = or >35 kg/m2
  • Fasting lipid level LDL>3.3 mmol/L, total cholesterol >5.2 mmol/L, and triglycerides > 2.24mmol/L
  • Non-compliance
  • Questionable validity of consent
  • Prior use of study medication or other drugs.
  • Affiliation with investigator site
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
446 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/Vilanterol

    Inhaled corticosteroid/long acting beta-agonist

    Drug: Fluticasone Furoate/Vilanterol

  • Experimental
    vilanterol

    Inhaled long acting beta-agonist

    Drug: Vilanterol

  • Placebo comparator
    placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168)

    PWV is defined as the speed of travel of the pressure pulse along an arterial segment and can be obtained for any arterial segment accessible to palpation. aPWV is measured with tonometers positioned transcutaneously at the base of the common carotid artery and over the femoral artery. PWV increases with arterial stiffness and is defined by the Moens-Korteweg equation: PWV=square root of (Eh/2ρR), where E is Young's modulus of the arterial wall, h is the wall thickness, R is the arterial radius at the end of diastole, and ρ is the blood density. Change from BL was calculated as the Day 168 value minus the BL value. The analysis was performed using a repeated measures model with covariates of treatment, visit, age, gender, smoking history, history of exacerbation strata, geographical region, BL aPWV and interaction terms of BL by visit and treatment by visit.

    Time frame: BL to Day 168

Secondary outcomes

  1. Change From BL in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 168

    Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry at Screening, Days 1, 28, 84, 126, and 168. BL FEV1 was defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 was defined as the mean of the FEV1 values obtained 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was preformed using a repeated measures model with covariates of visit, treatment, history of exacerbation strata, geographical region, BL FEV1 and interaction terms of BL by visit and treatment by visit.

    Time frame: BL to Day 168

  2. Mean Number of Occasions Rescue Medication [Albuterol (Salbutamol)] Used During a 24-hour Period Averaged Over the Entire 24-week Treatment Period

    Participants were given daily record cards for daily completion from BL (Week -1) through Week 24 (Visit 6) each morning and prior to taking study medication (i.e., single-blind and double-blind study medication) supplemental medication (albuterol \[salbutamol\] if received) and ipratropium bromide (if received). Participants recorded number of occasions supplemental albuterol/salbutamol (MDI and/or nebules) used over the previous 24 hours and any medical problems that they had experienced and any medication used to treat these medical problems over the previous 24 hours. Analysis was performed using an analysis of covarience (ANCOVA) model with covariates of treatment, BL mean of occasions of rescue medication use (Week -1), history of exacerbation, and geographical region.

    Time frame: BL (Week -1), Week 1 to Week 24

07

Results

Posted Jul 10, 2015

Participant flow

A total of 3011 participants (par.) were screened, 559 entered the Run-in Period (RIP), of whom 444 were randomized and received at least one dose of study medication; 430 of these were included in the Intent-to-Treat (ITT) Population.

2-week, Single-blind Run-In Period
Participant flow — 2-week, Single-blind Run-In Period
MilestonePlacebo-Run-inPlacebo QDVI 25 µg QDFF/VI 100/25 µg QD
Started559000
Completed444000
Not completed115000
Withdrew: Did not meet continuation criteria102000
Withdrew: Withdrawal by subject9000
Withdrew: Adverse event1000
Withdrew: Physician decision1000
Withdrew: Lost to follow-up2000
24-week, Double-blind Treatment Period
Participant flow — 24-week, Double-blind Treatment Period
MilestonePlacebo-Run-inPlacebo QDVI 25 µg QDFF/VI 100/25 µg QD
Started0141154135
Completed the treatment period096124110
Completed097124111
Not completed0443024
Withdrew: Adverse event0867
Withdrew: Lack of efficacy-no sub-reason0200
Withdrew: Lack of efficacy-sub-reason exacerbation013136
Withdrew: Protocol violation0433
Withdrew: Protocol-defined stopping criteria0436
Withdrew: Lost to follow-up0300
Withdrew: Physician decision0311
Withdrew: Withdrawal by subject0741

Outcome measures

PrimaryMean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168)

PWV is defined as the speed of travel of the pressure pulse along an arterial segment and can be obtained for any arterial segment accessible to palpation. aPWV is measured with tonometers positioned transcutaneously at the base of the common carotid artery and over the femoral artery. PWV increases with arterial stiffness and is defined by the Moens-Korteweg equation: PWV=square root of (Eh/2ρR), where E is Young's modulus of the arterial wall, h is the wall thickness, R is the arterial radius at the end of diastole, and ρ is the blood density. Change from BL was calculated as the Day 168 value minus the BL value. The analysis was performed using a repeated measures model with covariates of treatment, visit, age, gender, smoking history, history of exacerbation strata, geographical region, BL aPWV and interaction terms of BL by visit and treatment by visit.

Time frame:
BL to Day 168
Reported as:
Least squares mean · meters per second (m/sec)
Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168)
meters per second (m/sec)Placebo QDVI 25 µg QDFF/VI 100/25 µg QD
Mean Change From Baseline (BL) in Aortic Pulse Wave Velocity (aPWV) at the End of the 24-week Treatment Period (Day 168)-1.97 ± 0.279-1.95 ± 0.241-1.75 ± 0.256
Statistical analysis
  • Placebo QD vs VI 25 µg QD · Mixed Models Analysis · p = 0.969 · Least squares mean difference: 0.01 · 95% CI -0.71 to 0.74Restricted maximum likelihood (REML)-based repeated measures approach (MMRM)
  • Placebo QD vs FF/VI 100/25 µg QD · Mixed Models Analysis · p = 0.568 · Least squares mean difference: 0.22 · 95% CI -0.53 to 0.96Restricted maximum likelihood (REML)-based repeated measures approach (MMRM)
  • VI 25 µg QD vs FF/VI 100/25 µg QD · Mixed Models Analysis · p = 0.566 · Least squares mean difference: 0.20 · 95% CI -0.49 to 0.89Restricted maximum likelihood (REML)-based repeated measures approach (MMRM)
SecondaryChange From BL in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 168

Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry at Screening, Days 1, 28, 84, 126, and 168. BL FEV1 was defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 was defined as the mean of the FEV1 values obtained 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was preformed using a repeated measures model with covariates of visit, treatment, history of exacerbation strata, geographical region, BL FEV1 and interaction terms of BL by visit and treatment by visit.

Time frame:
BL to Day 168
Reported as:
Least squares mean · Liters (L)
Change From BL in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 168
Liters (L)Placebo QDVI 25 µg QDFF/VI 100/25 µg QD
Change From BL in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1 at Day 168-0.049 ± 0.02210.033 ± 0.02020.106 ± 0.0210
Statistical analysis
  • Placebo QD vs VI 25 µg QD · Mixed Models Analysis · p = 0.007 (Nominal p-value) · Least squares mean difference: 0.082 · 95% CI 0.023 to 0.141Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).
  • Placebo QD vs FF/VI 100/25 µg QD · Mixed Models Analysis · p = <0.001 (Nominal p-value) · Least squares mean difference: 0.155 · 95% CI 0.095 to 0.215Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).
  • VI 25 µg QD vs FF/VI 100/25 µg QD · Mixed Models Analysis · p = 0.012 (Nominal p-value) · Least squares mean difference: 0.074 · 95% CI 0.016 to 0.131Restricted maximum likelihood (REML)-based repeated measures approach (MMRM).
SecondaryMean Number of Occasions Rescue Medication [Albuterol (Salbutamol)] Used During a 24-hour Period Averaged Over the Entire 24-week Treatment Period

Participants were given daily record cards for daily completion from BL (Week -1) through Week 24 (Visit 6) each morning and prior to taking study medication (i.e., single-blind and double-blind study medication) supplemental medication (albuterol \[salbutamol\] if received) and ipratropium bromide (if received). Participants recorded number of occasions supplemental albuterol/salbutamol (MDI and/or nebules) used over the previous 24 hours and any medical problems that they had experienced and any medication used to treat these medical problems over the previous 24 hours. Analysis was performed using an analysis of covarience (ANCOVA) model with covariates of treatment, BL mean of occasions of rescue medication use (Week -1), history of exacerbation, and geographical region.

Time frame:
BL (Week -1), Week 1 to Week 24
Reported as:
Least squares mean · Occasions per 24 hours
Mean Number of Occasions Rescue Medication [Albuterol (Salbutamol)] Used During a 24-hour Period Averaged Over the Entire 24-week Treatment Period
Occasions per 24 hoursPlacebo QDVI 25 µg QDFF/VI 100/25 µg QD
Mean Number of Occasions Rescue Medication [Albuterol (Salbutamol)] Used During a 24-hour Period Averaged Over the Entire 24-week Treatment Period1.97 ± 0.0931.50 ± 0.0891.47 ± 0.095
Statistical analysis
  • Placebo QD vs VI 25 µg QD · ANCOVA · p = <0.001 (Nominal p-value) · Least squares mean difference: -0.47 · 95% CI -0.72 to -0.22
  • Placebo QD vs FF/VI 100/25 µg QD · ANCOVA · p = <0.001 (Nominal p-value) · Least squares mean difference: -0.50 · 95% CI -0.76 to -0.24
  • VI 25 µg QD vs FF/VI 100/25 µg QD · ANCOVA · p = 0.803 · Least squares mean difference: -0.03 · 95% CI -0.29 to 0.22

Adverse events

Collected over On-treatment serious adverse events (SAE) and non-serious AEs were collected from the start of the double-blind (DB) treatment period (Visit 2) through the follow-up contact (7 days after Visit 6 [Week 25]).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QD—5/145 (3.4%)24/145 (16.6%)
VI 25 µg QD—12/158 (7.6%)27/158 (17.1%)
FF/VI 100/25 µg QD—9/141 (6.4%)34/141 (24.1%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlacebo QDVI 25 µg QDFF/VI 100/25 µg QD
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1455/1582/141
PneumoniaInfections and infestations2/1451/1582/141
FaecalomaGastrointestinal disorders0/1450/1581/141
PyelonephritisInfections and infestations0/1450/1581/141
Fibula fractureInjury, poisoning and procedural complications0/1450/1581/141
Hip fractureInjury, poisoning and procedural complications0/1450/1581/141
Tibia fractureInjury, poisoning and procedural complications0/1450/1581/141
Hepatic enzyme increasedInvestigations0/1450/1581/141
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1450/1581/141
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1450/1581/141
Most frequent other events
Most frequent other events
EventPlacebo QDVI 25 µg QDFF/VI 100/25 µg QD
NasopharyngitisInfections and infestations5/14512/1589/141
Oral candidiasisInfections and infestations1/1452/1589/141
HeadacheNervous system disorders5/1459/1588/141
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/1452/1586/141
Upper respiratory tract infectionInfections and infestations6/1454/1582/141
ArthralgiaMusculoskeletal and connective tissue disorders4/1451/1585/141
Back painMusculoskeletal and connective tissue disorders5/1455/1584/141

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo QDVI 25 µg QDFF/VI 100/25 µg QDTotal
Mean68.2 ± 8.1068.7 ± 7.6968.5 ± 8.0168.5 ± 7.91
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QDVI 25 µg QDFF/VI 100/25 µg QDTotal
Female22363189
Male119118104341
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo QDVI 25 µg QDFF/VI 100/25 µg QDTotal
African American/African Heritage74617
Asian - Central/South Asian Heritage1001
Asian - East Asian Heritage21231862
Asian - South East Asian Heritage455147143
Asian - Mixed Race1001
White - Arabic/North African Heritage1102
White - White/Caucasian/European Heritage647564203
Mixed Race1001
08

Study locations

72 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Torrance, California 90505, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Gainesville, Florida 32608, United States
  • GSK Investigational Site
    Orlando, Florida 32825, United States
  • GSK Investigational Site
    Ormond Beach, Florida 32174, United States
  • GSK Investigational Site
    Winter Park, Florida 32789, United States
  • GSK Investigational Site
    Duluth, Georgia 30096, United States
  • GSK Investigational Site
    Coeur d'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Avon, Indiana 46123, United States
  • GSK Investigational Site
    Lafayette, Indiana 47904, United States
  • GSK Investigational Site
    Muncie, Indiana 47304-5547, United States
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
  • GSK Investigational Site
    Traverse City, Michigan 49684, United States
  • GSK Investigational Site
    Saint Charles, Missouri 63301, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Shelby, North Carolina 28152, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Columbus, Ohio 43215, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Fort Mill, South Carolina 29707, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Edinburg, Texas 78539, United States
  • GSK Investigational Site
    Abingdon, Virginia 24210, United States
  • GSK Investigational Site
    Elsterwerda, Brandenburg 04910, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01069, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23552, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Hamburg, 20253, Germany
  • GSK Investigational Site
    Ansan, 425-707, Korea, Republic of
  • GSK Investigational Site
    Gwangju, 501-757, Korea, Republic of
  • GSK Investigational Site
    Ilsanseo-gu, Goyang-si, Gyeonggi-do, 411706, Korea, Republic of
  • GSK Investigational Site
    Pusan, 614-735, Korea, Republic of
  • GSK Investigational Site
    Seoul, 134-090, Korea, Republic of
  • GSK Investigational Site
    Seoul, 134060, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Elverum, 2408, Norway
  • GSK Investigational Site
    Kløfta, 2040, Norway
  • GSK Investigational Site
    Moss, 1501, Norway
  • GSK Investigational Site
    Stavanger, 4005, Norway
  • GSK Investigational Site
    Dagupan City, 2400, Philippines
  • GSK Investigational Site
    Jaro, Iloilo City, 5000, Philippines
  • GSK Investigational Site
    Manila, 1000, Philippines
  • GSK Investigational Site
    Marilao, Bulacan, 3019, Philippines
  • GSK Investigational Site
    Pasig City, 1600, Philippines
  • GSK Investigational Site
    Quezon City, 1100, Philippines
  • GSK Investigational Site
    Bangkok, 10400, Thailand
  • GSK Investigational Site
    Bangkok, 10700, Thailand
  • GSK Investigational Site
    Chiangmai, 50200, Thailand
  • GSK Investigational Site
    Khon Kaen, 40002, Thailand
  • GSK Investigational Site
    Muang, 11000, Thailand
  • GSK Investigational Site
    Muang, 65000, Thailand
  • GSK Investigational Site
    Nan, 55000, Thailand
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Nov 2014, 44 months.

Results were first posted in Jul 2015, 8 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 44 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2011
First posted
Apr 18, 2011
StartActual
Mar 4, 2011
Primary completionActual
Nov 4, 2014
CompletionActual
Nov 4, 2014
Results first posted
Jul 10, 2015
Last update
Nov 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01336608
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 18, 2011
Start date
Mar 4, 2011
Primary completion
Nov 4, 2014
Completion
Nov 4, 2014
Results posted
Jul 10, 2015
Last update
Nov 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion